Netanyahu's defence push: Israel approves purchase of F-35 and F-15IA fighter jets to boost air power

Israel approved a multi-billion-dollar procurement of two new combat squadrons, including F-35 and F-15IA jets, as part of a 350 billion shekel ($119 billion) defence modernization plan. The expansion reportedly doubles the planned F-35 fleet to 100 aircraft and raises the F-15IA fleet to 50, with deliveries expected into the early 2030s. The move strengthens Israel’s long-term air superiority but is unlikely to directly move equity markets beyond defence and aerospace sentiment.

Analysis

This is less a one-off procurement headline than a multi-year demand signal for Western aerospace supply chains. The bigger second-order effect is that Israel is effectively pre-committing to a higher sortie-capacity doctrine, which should support not just airframe revenue but a deeper stack of avionics, mission systems, sustainment, munitions, and classified integration work that tends to re-rate programs with recurring aftermarket economics. That favors prime contractors and select electronics suppliers more than it favors short-cycle headline traders.

For LMT, the strategic value is better than the near-term financial value: F-35 backlog is already long, but incremental international demand improves pricing power on sustainment and software upgrades while reinforcing the program’s geopolitical moat. For BA, this is more incremental because the F-15 line matters more for factory utilization and labor absorption than for margin expansion; the real upside is a longer production runway and reduced risk of underutilization, though execution on fixed-price defense work remains the key limiter. The hidden winner may be U.S.-based subcontractors with export-content exposure, as allied restocking and higher Israeli readiness spending create a sustained pull-through cycle.

The contrarian risk is that investors may be overpricing the timing of cash flow. Approvals are not deliveries, and a meaningful portion of the budget will leak into domestic Israeli production and long-dated integration work, so near-term EPS uplift for primes is likely modest. The real catalyst path is 12-36 months: delivery milestones, sustainment add-ons, and follow-on munitions orders. If regional risk premia normalize or U.S. export politics tighten, the headline can remain bullish while the actual revenue timing slips.

The move looks underpriced in terms of industrial base implications but fairly priced in terms of near-term multiple expansion. The best expression is not an outright momentum chase; it is to own the names with the cleanest backlog conversion and highest aftermarket mix while fading any outsized reaction in the less levered prime.

Key Decisions for Investors

• Long LMT on a 6-12 month horizon; favor on pullbacks rather than strength. Best risk/reward is driven by backlog durability and sustainment mix, with downside limited unless export approvals or program execution deteriorate.
• Small tactical long BA only if the stock lags LMT after the headline. Use a 3-6 month horizon and treat it as a utilization/production-line trade, not a margin expansion story; exit if defense order flow fails to translate into visible schedule support.
• Pair trade: long LMT / short BA for 3-9 months. Thesis is that LMT has cleaner conversion to recurring revenue and less operational friction, while BA’s upside is more execution-sensitive and slower to monetize.
• Buy medium-dated calls on LMT if implied vol remains below realized geopolitical volatility; structure for 6-12 months to capture follow-on contract and sustainment headlines, with defined premium risk.
• Avoid chasing a broad defense ETF here; prefer single-name exposure because the second-order benefit is concentrated in program-specific backlog and aftermarket economics rather than sector-wide beta.